![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Gallwitz Baptist
Publisher: Adis International
ISSN: 0114-5916
Source: Drug Safety, Vol.33, Iss.2, 2010-02, pp. : 87-100
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
Drug Safety, Vol. 20, Iss. 6, 1999-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Exenatide enhances standard therapy in type 2 diabetes mellitus
Inpharma, Vol. 1, Iss. 1445, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)